Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pancreatic Neoplasms 2Glioblastoma 2Triple Negative Breast Neoplasms 1Gliosarcoma 1Glioma 1Breast Neoplasms 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Radiotherapy 4Radiation 3trametinib 2dabrafenib 2Radiotherapy, Intensity-Modulated 2Bevacizumab 2vorasidenib 1veliparib 1trastuzumab deruxtecan 1ribociclib 1Spinal Puncture 1Protons 1Proton Therapy 1Pluvicto 1Nivolumab 1Magnetic Resonance Imaging 1Ipilimumab 1Flucytosine 1Everolimus 1Carboplatin 1CTLA-4 Antigen 1AZD1390 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × veliparib × 30 days × Clear all
NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡